Abeona Therapeutics Inc. (ABEO) Stock Forecast
ABEO analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 7 analysts
- Price target
- $18.88 average of analyst targets
- Upside to target
- +326.1% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.14
- 52-week range
- $4.17 – $7.46
ABEO analyst ratings
7 analystsNumber of analysts at each rating.
ABEO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ABEO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.25 | −$0.05 | −$0.11 | −57.4% | 4 |
| Current fiscal year (2026) | −$0.95 | −$1.15 | −$0.72 | −$1.24 | +23.1% | 4 |
| Next fiscal year (2027) | −$0.21 | −$0.83 | $0.42 | −$0.95 | +78.2% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ABEO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $14.8M | $11.4M | $21.6M | 0.0% | 8 |
| Current fiscal year (2026) | $52.6M | $43.0M | $66.0M | +804.3% | 8 |
| Next fiscal year (2027) | $115.6M | $79.0M | $156.0M | +119.7% | 8 |
ABEO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ABEO revenue: reported and forecast
ABEO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.11 | −$0.13 | −$0.11 | −$0.17 | +54.5% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.68 | −$0.68 | −$0.87 | −$0.83 | −$0.95 | +39.0% | 0 up · 1 down |
| Next fiscal year (2027) | $0.29 | $0.29 | −$0.19 | −$0.04 | −$0.21 | −172.4% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ABEO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ABEO beat in 6 of 12.
What analysts expect from ABEO
7 analysts cover Abeona Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $18.88, 326.1% above the latest close of $4.43. Analysts expect earnings of −$0.95 per share for 2026, +23.1% from a year earlier. For 2027 the average estimate is −$0.21 per share on revenue of $115.6 million. Abeona Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: ABEO income statement, ABEO key metrics, ABEO chart. See the ABEO stock overview for the latest quote and news.
ABEO forecast FAQ
What is Abeona Therapeutics's price target?
The average analyst price target for Abeona Therapeutics is $18.88, 326.1% above the latest close of $4.43.
Is Abeona Therapeutics a buy, hold or sell?
Of 7 analysts covering Abeona Therapeutics, 7 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Abeona Therapeutics's EPS forecast?
Analysts forecast −$0.95 per share for 2026 (range −$1.15 to −$0.72); for 2027 the estimate is −$0.21.
What is Abeona Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $52.6 million, growth of 804.3%; for 2027 it is $115.6 million.
When does Abeona Therapeutics report earnings?
Abeona Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens; the EPS estimate is $-0.14.
Does Abeona Therapeutics usually beat earnings estimates?
Abeona Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.